185 related articles for article (PubMed ID: 7481844)
1. Schedule-dependent antitumor effect of gemcitabine in in vivo model system.
Braakhuis BJ; Ruiz van Haperen VW; Boven E; Veerman G; Peters GJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):42-6. PubMed ID: 7481844
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors.
Veerman G; Ruiz van Haperen VW; Vermorken JB; Noordhuis P; Braakhuis BJ; Pinedo HM; Peters GJ
Cancer Chemother Pharmacol; 1996; 38(4):335-42. PubMed ID: 8674156
[TBL] [Abstract][Full Text] [Related]
3. Interaction between cisplatin and gemcitabine in vitro and in vivo.
Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
[TBL] [Abstract][Full Text] [Related]
4. Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer.
Braakhuis BJ; van Dongen GA; Vermorken JB; Snow GB
Cancer Res; 1991 Jan; 51(1):211-4. PubMed ID: 1988086
[TBL] [Abstract][Full Text] [Related]
5. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.
Boven E; Schipper H; Erkelens CA; Hatty SA; Pinedo HM
Br J Cancer; 1993 Jul; 68(1):52-6. PubMed ID: 8318420
[TBL] [Abstract][Full Text] [Related]
6. Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine).
Fields MT; Eisbruch A; Normolle D; Orfali A; Davis MA; Pu AT; Lawrence TS
Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):785-91. PubMed ID: 10837965
[TBL] [Abstract][Full Text] [Related]
7. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
8. [Antitumor activity of LY 188011, a new deoxycytidine analog, against human cancers xenografted into nude mice].
Fujita M; Fujita F; Inaba H; Taguchi T
Gan To Kagaku Ryoho; 1994 Mar; 21(4):517-23. PubMed ID: 8129393
[TBL] [Abstract][Full Text] [Related]
9. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts.
Braakhuis BJ; Ruiz van Haperen VW; Welters MJ; Peters GJ
Eur J Cancer; 1995 Dec; 31A(13-14):2335-40. PubMed ID: 8652266
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy using gemcitabine and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin.
Koppe MJ; Oyen WJ; Bleichrodt RP; Verhofstad AA; Goldenberg DM; Boerman OC
Cancer Biother Radiopharm; 2006 Oct; 21(5):506-14. PubMed ID: 17105422
[TBL] [Abstract][Full Text] [Related]
11. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
Ruiz van Haperen VW; Veerman G; Boven E; Noordhuis P; Vermorken JB; Peters GJ
Biochem Pharmacol; 1994 Oct; 48(7):1327-39. PubMed ID: 7945430
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of 2',2'-difluorodeoxycytidine (gemcitabine) and vinblastine combined with interferon in nude mice xenografts of human renal cell carcinoma.
Rohde D; Goertz M; Blatter J; Jakse G
Int J Oncol; 1998 Jun; 12(6):1367-72. PubMed ID: 9592201
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.
Lund B; Hansen OP; Theilade K; Hansen M; Neijt JP
J Natl Cancer Inst; 1994 Oct; 86(20):1530-3. PubMed ID: 7932808
[TBL] [Abstract][Full Text] [Related]
15. Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels.
Moog R; Burger AM; Brandl M; Schüler J; Schubert R; Unger C; Fiebig HH; Massing U
Cancer Chemother Pharmacol; 2002 May; 49(5):356-66. PubMed ID: 11976829
[TBL] [Abstract][Full Text] [Related]
16. Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study.
Poplin EA; Corbett T; Flaherty L; Tarasoff P; Redman BG; Valdivieso M; Baker L
Invest New Drugs; 1992 Aug; 10(3):165-70. PubMed ID: 1428726
[TBL] [Abstract][Full Text] [Related]
17. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation.
Patel SR; Gandhi V; Jenkins J; Papadopolous N; Burgess MA; Plager C; Plunkett W; Benjamin RS
J Clin Oncol; 2001 Aug; 19(15):3483-9. PubMed ID: 11481354
[TBL] [Abstract][Full Text] [Related]
18. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
Tonkinson JL; Worzalla JF; Teng CH; Mendelsohn LG
Cancer Res; 1999 Aug; 59(15):3671-6. PubMed ID: 10446980
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo.
Iizuka K; Zhang C; Eshima K; Jin C; Eshima K; Fukushima M
Int J Oncol; 2018 Mar; 52(3):851-860. PubMed ID: 29344636
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model.
Joschko MA; Webster LK; Groves J; Yuen K; Palatsides M; Ball DL; Millward MJ
Radiat Oncol Investig; 1997; 5(2):62-71. PubMed ID: 9303059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
